Latest Insider Transactions at Mereo Biopharma Group PLC (MREO)
This section provides a real-time view of insider transactions for Mereo Biopharma Group PLC (MREO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Mereo Biopharma Group plc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Mereo Biopharma Group plc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 13
2024
|
Denise Scots Knight Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
60,046
-6.91%
|
$240,184
$4.22 P/Share
|
|
Sep 13
2024
|
Alexandra Hughes Wilson |
SELL
Open market or private sale
|
Direct |
100,312
-36.64%
|
$401,248
$4.22 P/Share
|
|
Sep 13
2024
|
Christine Ann Fox Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
19,158
-17.67%
|
$76,632
$4.22 P/Share
|
|
Sep 13
2024
|
Charles Sermon General Counsel |
SELL
Open market or private sale
|
Direct |
20,946
-8.73%
|
$83,784
$4.22 P/Share
|
|
Sep 13
2024
|
John A. Lewicki Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,937
-12.21%
|
$43,748
$4.22 P/Share
|
|
Sep 12
2024
|
Denise Scots Knight Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
28,611
-3.19%
|
$114,444
$4.47 P/Share
|
|
Sep 12
2024
|
Alexandra Hughes Wilson |
SELL
Open market or private sale
|
Direct |
47,798
-12.45%
|
$191,192
$4.47 P/Share
|
|
Sep 12
2024
|
Christine Ann Fox Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,128
-7.76%
|
$36,512
$4.47 P/Share
|
|
Sep 12
2024
|
Charles Sermon General Counsel |
SELL
Open market or private sale
|
Direct |
9,980
-3.99%
|
$39,920
$4.47 P/Share
|
|
Sep 12
2024
|
John A. Lewicki Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,212
-5.5%
|
$20,848
$4.47 P/Share
|
|
Sep 11
2024
|
Charles Sermon General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
65,600
+20.79%
|
-
|
|
Sep 11
2024
|
Christine Ann Fox Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+33.79%
|
-
|
|
Sep 11
2024
|
Alexandra Hughes Wilson |
BUY
Exercise of conversion of derivative security
|
Direct |
208,333
+31.41%
|
$0
$0.8 P/Share
|
|
Sep 11
2024
|
Denise Scots Knight Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
188,060
+17.32%
|
-
|
|
Sep 11
2024
|
John A. Lewicki Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
46,000
+32.68%
|
-
|
|
Aug 22
2024
|
Deepika Pakianathan |
SELL
Open market or private sale
|
Direct |
105,244
-100.0%
|
$420,976
$4.43 P/Share
|
|
Aug 22
2024
|
Deepika Pakianathan |
BUY
Exercise of conversion of derivative security
|
Direct |
105,244
+33.73%
|
$210,488
$2.28 P/Share
|
|
Jun 26
2024
|
Alexandra Hughes Wilson |
SELL
Open market or private sale
|
Direct |
22,968
-39.93%
|
$68,904
$3.39 P/Share
|
|
Jun 26
2024
|
Denise Scots Knight Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
92,273
-11.51%
|
$276,819
$3.39 P/Share
|
|
Jun 26
2024
|
Christine Ann Fox Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
29,439
-33.83%
|
$88,317
$3.39 P/Share
|
|
Jun 26
2024
|
John A. Lewicki Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
16,808
-25.63%
|
$50,424
$3.39 P/Share
|
|
Jun 26
2024
|
Charles Sermon General Counsel |
SELL
Open market or private sale
|
Direct |
32,187
-14.86%
|
$96,561
$3.39 P/Share
|
|
Jun 25
2024
|
Alexandra Hughes Wilson |
SELL
Open market or private sale
|
Direct |
10,134
-14.98%
|
$30,402
$3.69 P/Share
|
|
Jun 25
2024
|
Denise Scots Knight Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
40,712
-4.83%
|
$122,136
$3.69 P/Share
|
|
Jun 25
2024
|
Christine Ann Fox Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
12,990
-12.99%
|
$38,970
$3.69 P/Share
|
|
Jun 25
2024
|
John A. Lewicki Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,416
-10.16%
|
$22,248
$3.69 P/Share
|
|
Jun 25
2024
|
Charles Sermon General Counsel |
SELL
Open market or private sale
|
Direct |
14,202
-6.15%
|
$42,606
$3.69 P/Share
|
|
Jun 21
2024
|
John A. Lewicki Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
69,000
+48.59%
|
-
|
|
Jun 21
2024
|
Denise Scots Knight Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
282,090
+25.08%
|
-
|
|
Jun 21
2024
|
Alexandra Hughes Wilson |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+47.0%
|
-
|
|
Jun 21
2024
|
Christine Ann Fox Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
90,000
+47.37%
|
-
|
|
Jun 21
2024
|
Charles Sermon General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
98,400
+29.89%
|
-
|
|
Jun 17
2024
|
Jeremy Bender |
BUY
Grant, award, or other acquisition
|
Indirect |
12,550
+50.0%
|
$37,650
$3.99 P/Share
|
|
Jun 17
2024
|
Michael S Wyzga |
BUY
Grant, award, or other acquisition
|
Direct |
25,050
+50.0%
|
$75,150
$3.99 P/Share
|
|
May 22
2024
|
Alexandra Hughes Wilson |
SELL
Payment of exercise price or tax liability
|
Direct |
67,901
-80.7%
|
$67,901
$1.21 P/Share
|
|
May 22
2024
|
Alexandra Hughes Wilson |
SELL
Open market or private sale
|
Direct |
100,432
-53.4%
|
$200,864
$2.97 P/Share
|
|
May 22
2024
|
Alexandra Hughes Wilson |
BUY
Exercise of conversion of derivative security
|
Direct |
168,333
+47.8%
|
$168,333
$1.21 P/Share
|